Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01062932 · ClinicalTrials.gov registry record · Phase 1
Investigation of Cycloserine as a Smoking Cessation Treatment
A Phase 1 study of Nicotine Addiction, sponsored by Baylor College of Medicine.
- Completed
- Registry status
- Phase 1
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT01062932 is a Phase 1 study of Nicotine Addiction that has completed, run by Baylor College of Medicine. The registered enrollment target is 34 participants, below the 721-participant average among 10 other Nicotine Addiction trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.
The verdict
NCT01062932, a Phase 1 study of Nicotine Addiction, has completed, sponsored by Baylor College of Medicine.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
Psychosocial treatments for drug abuse benefit some patients (Rawson et al 2004), but there is an urgent need for new treatment approaches that can improve treatment outcomes. One new approach involves facilitation of extinction of conditioned responses through the use of d-cycloserine, a partial agonist at the NMDA glycine site. This approach has proved useful for the treatment of several anxiety disorders. For example, treatment with d-cycloserine enhanced the efficacy of behavioral treatments for acrophobia (Ressler et al 2004) and social phobia (Hofmann et al 2006) by enhancing extinction of conditioned fear responses. This suggests that d-cycloserine has potential to enhance the efficacy of behavioral treatments for drug dependence by enhancing extinction of conditioned responses to drug cues. In this Phase I Cutting-Edge Basic Research Awards (CEBRA) application we propose a proof-of-concept study to examine effects of treatment with d-cycloserine for facilitating extinction of craving provoked by exposure to cigarette smoking cues. The benefits of this treatment approach together with cognitive behavioral treatment for reducing cigarette smoking will then be determined. Smoking cues will be presented using an established virtual reality simulator(Bordnick et al 2004; Bordnick et al 2005a)
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Cycloserine
Study Locations (1)
Texas
- Michael E. DeBakey VA Medical Center - Houston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2009-05 |
| Est. Completion | 2010-09 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01062932
The ClinicalTrials.gov registry entry for NCT01062932 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 34 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 721-participant average among 10 other Nicotine Addiction trials with a reported enrollment target (95% lower). The listed sponsor is Baylor College of Medicine, which has 616 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Nicotine Addiction appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT01062932 reports 1 study location spanning 1 distinct geographic area - top geographies include Texas.
Frequently Asked Questions
What is clinical trial NCT01062932 about?
NCT01062932 is a clinical study titled "Investigation of Cycloserine as a Smoking Cessation Treatment". Psychosocial treatments for drug abuse benefit some patients (Rawson et al 2004), but there is an urgent need for new treatment approaches that can improve treatment outcomes. One new approach involves facilitation of extinction of conditioned responses through the use of d-cycloserine, a partial ag...
What is the current status of trial NCT01062932?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 34 participants. The study started on 2009-05. Estimated completion is 2010-09.
What conditions does trial NCT01062932 study?
This clinical trial studies the following conditions: Nicotine Addiction.
What interventions are being tested in trial NCT01062932?
The interventions under investigation include: Placebo (DRUG), Cycloserine (DRUG).
Who is sponsoring clinical trial NCT01062932?
This trial is sponsored by Baylor College of Medicine, which has 616 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01062932 being conducted?
This trial has 1 study location across Texas. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Nicotine Addiction
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Effect of Product Characteristics on the Abuse Liability of Nicotine Pouches
RECRUITING · NA
-
Advancing VR-based Attentional Bias as a Biomarker for Tobacco Use Disorder
RECRUITING · Early Phase 1
-
CONNECT Cancer Survivors With Tobacco Treatment
RECRUITING · NA
-
Circuitry-Guided Smoking Cessation in Schizophrenia (UH3)
RECRUITING · NA
-
Cognitive Training for Nicotine Dependence
COMPLETED · NA
-
Effects of Brief Training on Craving Regulation
COMPLETED · NA
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.